Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome

Angiology

Volumn 60, Issue 1, 2009, Pages 87-92

  Barylski, Marcin ^a   Kowalczyk, Edward ^a   Banach, Maciej ^a   Ciećwierz, Julita ^a   Pawlicki, Lucjan ^a   Kowalski, Jan ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Metabolic syndrome; Nitric oxide; Plasma total antioxidant activity; Vascular endothelial growth factor

Indexed keywords

NITRIC OXIDE; VASCULOTROPIN;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X;

ADULT; AGED; ANTIOXIDANTS; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; DOWN-REGULATION; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; NITRIC OXIDE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 59149106393     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319708327165     Document Type: Article

References (38)

1. Wang CY, Liao JK Current advances in statin treatment: from molecular mechanisms to clinical practice. Arch Med Sci. 2007 ; 3: S91 - S96.
2. Verma S., Anderson TJ Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002 ; 105: 546-549.
3. Vita JA, Loscalzo J. Shouldering the risk burden: infection, atherosclerosis, and the vascular endothelium. Circulation. 2002 ; 106: 164-166.
4. Prasad A., Zhu J., Halcox JP, Waclawiw MA, Epstein SE, Quyyumi AA Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation. 2002 ; 106: 184-190.
5. Guzik TJ, West NE, Black E., et al. Vascular superoxide production by NAD(P)H oxidase association with endothelial dysfunction and clinical risk factors. Circ Res. 2000 ; 86: e85 - e90.
6. Thomas KA Vascular endothelial growth factor, a potent and selective angiogenic agent. J Biol Chem. 1996 ; 271: 603-606.
7. Ziche M., Morbidelli L., Choudhuri R., et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest. 1997 ; 99: 2625-2634.
8. Dembińska-Kieć A., Dulak J., Partyka Ł., Huk I., Malinski T. VEGF-nitric oxide reciprocal regulation. Nat Med. 1997 ; 3: 1177.
9. Daskalopoulou SS, Mikhailidis DP, Elisaf M. Prevention and treatment of the metabolic syndrome. Angiology. 2004 ; 55: 589-612.
10. Benzie IF, Strain JJ Ferric reducing/antioxidant power assay: direct measure of total antioxidant activity of biological fluids and modified version for simultaneous measurement of total antioxidant power and ascorbic acid concentration. Methods Enzymol. 1999 ; 299: 15-27.
11. Bartosz G., Janaszewska A., Ertel D. Spectrophotometric determination of peroxyl radical-trapping capacity with ABAP and ABTS. Curr Topics Biophys. 1998 ; 22: 11-13.
12. Kowalski J., Barylski M., Banach M., Grycewicz J., Irzmanski R., Pawlicki L. Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J Cardiovasc Pharmacol. 2006 ; 48: 143-147.
13. Banach M., Markuszewski L., Zasłonka J., Grzegorczyk J., Okonski P., Jegier B. The role of inflammation in the pathogenesis of atherosclerosis. Przegl Epidemiol. 2004 ; 58: 663-670.
14. Dodani S., Marion L., Sharma G., Reed GL, George V. The association of carotid intima media thickness with dysfunctional HDL in South Asians. Arch Med Sci. 2008 ; 4: 40-46.
15. Höyssä S., Rontu R., Kuukasjärvi P., et al. Aspirin and statin medication decreases the risk of myocardial infarction associated with LTA and NFKBIL1 polymorphisms. Cent Eur J Med. 2006 ; 1: 237-249.
16. Tziomalos K., Athyros VG, Karagiannis A., Mikhailidis DP Endothelial function, arterial stiffness and lipid lowering drugs. Expert Opin Ther Targets. 2007 ; 11: 1143-1160.
17. Lantos J., Roth E., Czopf L., Nemes J., Gál I. Monitoring of plasma total antioxidant status in different diseases. Acta Chir Hung. 1997 ; 36: 188-189.
18. Digiesi V., Fiorillo C., Cosmi L., et al. Reactive oxygen species and antioxidant status in essential arterial hypertension during therapy with dihydropyridine calcium channel antagonists. Clin Ter. 2000 ; 151: 15-18.
19. Risau W. Mechanisms of angiogenesis. Nature. 1997 ; 386: 671-674.
20. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis. Kidney Int. 1999 ; 56: 794-814.
21. Dulak J., Jozkowicz A. Nitric oxide in vascular endothelial growth factor synthesis and signaling. Circulation. 2001 ; 104: E48 - E49.
22. Ho QT, Kuo CJ Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol. 2007 ; 39: 1349-1357.
23. Gupta K., Kshirsagar S., Li W., et al. VEGF prevents apoptosis of human microvascular endothelial cells via opposing effects on MAPK/ERK and SAPK/JNK signaling. Exp Cell Res. 1999 ; 247: 495-504.
24. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996 ; 16: 4604-4613.
25. Carmeliet P., Dor Y., Herbert JM, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature. 1998 ; 394: 485-490.
26. Murohara T., Asahara T., Silver M., et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998 ; 101: 2567-2578.
27. Dulak J., Jozkowicz A., Dembińska-Kieć A., et al. Nitric oxide induces the synthesis of vascular endothelial growth factor in rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000 ; 20: 659-666.
28. Hiasa K., Ishibashi M., Ohtani K., et al. Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization. Circulation. 2004 ; 109: 2454-2461.
29. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P., Creager MA Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J Clin Invest. 1996 ; 97: 22-28.
30. Okonski P., Banach M., Rysz J., et al. L-arginine improves hemodynamic function and coronary flow in an experimental model of ischemia-reperfusion injury. Ann Transplant. 2006 ; 11: 28-34.
31. Dubois-Rande JL, Zelinsky R., Roudot F., et al. Effects of infusion of L-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous coronary arteries. Am J Cardiol. 1992 ; 70: 1269-1275.
32. Goch A., Banach M., Mikhailidis DP, Goch JH Endothelial dysfunction in patients with non-complicated and complicated hypertension. Clin Exp Hypertens. 2008 ; 30 :IN PRESS.
33. Stamler JS, Loh E., Roddy MA, Currie KE, Creager MA Nitric oxide regulates basal systemic and pulmonary vascular resistance in healthy humans. Circulation. 1994 ; 89: 2035-2040.
34. Gryglewski RJ, Palmer RM, Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature. 1986 ; 320: 454-456.
35. Vasquez-Vivar J., Kalyanaraman B., Martasek P., et al. Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc Natl Acad Sci U S A. 1998 ; 95: 9220-9225.
36. Rysz J., Banach M., Stolarek RA, et al. TNF-alfa priming effect on polymorphonuclear leukocytes reactive oxygen species generation and adhesion molecule expression in hemodialyzed patients. Arch Immunol Ther Exp. 2006 ; 54: 209-215.
37. Polus M., Polus A., Pawlus E., et al. Oxidized low density lipoprotein (ox-LDL) inhibits inducible nitric oxide synthase (iNOS) gene induction in rat vascular smooth muscle cells (VSMC). Acta Angiol. 1997 ; 1: 13-19.
38. Kowalski J., Banach M., Barylski M., Irzmanski R., Pawlicki L. Carvedilol modifies antioxidant status of patients with stable angina. Cell Mol Biol Lett. 2008 ; 13: 230-239.